The purpose of the filing is to issue new shares of common stock or dispose treasury shares in a timely and flexible manner in association with the continued implementation of a Long Term Incentive Plan ('LTIP'). For details of the LTIP, please refer to 'Launch of a New Employee Stock Purchase Plan and Long Term Incentive Plan for Company Group Employees Overseas' released on
Class of Securities to be Offered: Shares of common stock of the Company
Scheduled Issue Period: For the period from the scheduled effective date of the Shelf Registration to the date that is one year after such scheduled effective date
Scheduled Issue Amount: Up to
Use of Proceeds: The issuance of new shares of common stock or disposition of treasury shares related to the Shelf Registration will be conducted based on the LTIP and is not intended to raise funds.
Terms of Offering: To be determined.
The scheduled issue amount above is the estimated maximum total of both (1) the number of LTIP units that will vest and (2) the number of LTIP units that will be granted during the scheduled issue period, calculated under certain conditions. Share dilution during the fiscal year ending
This announcement has been prepared to publicly disclose the filing of a Shelf Registration Statement in
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
Contact:
Email: christopher.oreilly@takeda.com
Tel: +81 (0) 3-3278-2543
Email: takeda.ir.contact@takeda.com
Tel: +81 (0) 3-3278-2306
(C) 2024 Electronic News Publishing, source